An interventional study of RNA and/or DNA methylation and/or protein analysis in Neurogenetic Diseases, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Central Nervous System Diseases with a site in France — 15 open to participants now, 17 under way, 1 of them phase 3. Central Nervous System Diseases · France.
Among the 46 studies in Central Nervous System Diseases with a site in France, this one is the 21st largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 43rd registered.
386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.
Browse Central Nervous System Diseases studies →15 of the 46 studies in Central Nervous System Diseases with a site in France are open now. Recruiting first, the newest first:
MapLight Therapeutics · Sites in France, United States, Argentina and 12 more countries
Ages 55–90
iECURE, Inc. · Sites in France, United States, United Kingdom
Ages 7 mo–15 mo
University Hospital, Limoges · Sites in France
Ages 35–75
REGEnLIFE SAS · Sites in France
Ages 55–85
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 76 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 22 (29%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 13
First in 2008; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 95 is above the median of 52 across 296 interventional studies indexed under Central Nervous System Diseases.
Median enrollment 183 across the 34 interventional studies, 110 across the 12 observational. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
University Hospital, Rouen has 1 study filed under Central Nervous System Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Central Nervous System Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04194619Hospices Civils de LyonPregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study | 2027-02 |
| NCT06053619University Hospital, LimogesTolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients | 2027-03-11 |
| NCT05926011REGEnLIFE SASEfficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease | 2027-06 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Central Nervous System Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many neurological disorders show a strong genetic basis, from hereditary diseases caused by a single mutation in a given gene, to diseases caused by combinations of strong genetic risk factors. However, even after the sequencing of the appropriate genes, a large proportion of patients remains undiagnosed, either because there is no candidate mutation observed, or in case of identification of a candidate mutation with insufficient knowledge to consider it as pathogenic or not.
The aim of this project is to identify the cause of neurogenetic diseases in patients in situations of diagnostic wandering or dead ends by proposing the analysis of RNA and/or proteins from different tissues.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For this project, the inclusion of 3 participant profiles is required:
For all 3 groups:
Exclusion Criteria:
For patients with inconclusive results: Patient with a neurological disease not suspected of a monogenic or oligogenic cause
For healthy relatives: existence of a neurological disease (other than uncomplicated migraine) or psychiatric disease (other than simple anxiety stable under treatment).
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Patients with neurological disease affecting the central nervous system, of confirmed monogenic or probable oligogenic cause (positive controls * Unaffected relatives, showing no symptoms of the disease after the expected age of onset of symptoms in the family
Genetic: RNA and/or DNA methylation and/or protein analysis
RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells
number and proportion of patients
number and proportion of patients in the "Patients with inconclusive results" group for whom a final diagnosis can be made at the end of this research.
Time frame: through study completion, an average of 5 years
Inclusion
Inclusion of at least 50 participants with successful implementation of at least two procedures (see below, list of procedures)
Time frame: through study completion, an average of 5 years
Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes.
Identification of at least one candidate biomarker linked to one or more abnormalities of a gene or group of genes.
Time frame: through study completion, an average of 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2030, 60 months after the start.
Of 77 non-industry interventional studies with no phase under Central Nervous System Diseases, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 60 months is above that.
Counting every sponsor, half of 88 studies reached it within 38 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Nervous System Diseases →